SAPS-040 - Waiting times to start treatment with medications for opioid use disorder among US Medicaid Recipients, 1999-2020

• At: Copenhagen (Denmark) (2025)
• Type: Poster
• Poster code: SAPS-040
• By: HSU, Yu-Chia (Sam) (Center for Real-World Effectiveness and Safety of Therapeutics (CREST), Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, United States)
• Co-author(s): Dr Yu-Chia (Sam) Hsu (Center for Real-World Effectiveness and Safety of Therapeutics (CREST), Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia , United States)
  Prof Charles E Leonard (Center for Real-World Effectiveness and Safety of Therapeutics (CREST), Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia , United States)
  Prof Ashish P Thakrar (Division of General Internal Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia , United States)
  Ms. Colleen M Brensinger (Center for Real-World Effectiveness and Safety of Therapeutics (CREST), Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia , United States)
  Prof Warren B Bilker (Center for Real-World Effectiveness and Safety of Therapeutics (CREST), Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia , United States)
  Prof Sean Hennessy (Center for Real-World Effectiveness and Safety of Therapeutics (CREST), Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia , United States)
  
• Abstract:

  Background
  Medicaid is the single largest insurer in the US for individuals with opioid use disorder (OUD). Buprenorphine and methadone are first-line medications for OUD (MOUD) and timely access to MOUD is critical to reduce overdose deaths. However, among persons who receive MOUD, the waiting time to first receipt of MOUD has not been well..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login